

Accepted Manuscript

Factor Xa inhibition and sPESI failure in intermediate-high-risk pulmonary embolism

Alejandro R. Trevino, Luis Perez, Carlos Jerjes-Sanchez, David Rodriguez, Jathniel Pannefle, Claudia Ortiz-Ledesma, Francisco Nevarez, Vicente Jimenez, Felipe Valdes, Eduardo de Obeso



PII: S0735-6757(18)30533-3
DOI: doi:[10.1016/j.ajem.2018.06.054](https://doi.org/10.1016/j.ajem.2018.06.054)
Reference: YAJEM 57634
To appear in: *American Journal of Emergency Medicine*
Received date: 23 May 2018
Revised date: 21 June 2018
Accepted date: 21 June 2018

Please cite this article as: Alejandro R. Trevino, Luis Perez, Carlos Jerjes-Sanchez, David Rodriguez, Jathniel Pannefle, Claudia Ortiz-Ledesma, Francisco Nevarez, Vicente Jimenez, Felipe Valdes, Eduardo de Obeso, Factor Xa inhibition and sPESI failure in intermediate-high-risk pulmonary embolism. Yajem (2018), doi:[10.1016/j.ajem.2018.06.054](https://doi.org/10.1016/j.ajem.2018.06.054)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Factor Xa Inhibition and sPESI Failure in Intermediate-High-Risk Pulmonary Embolism

Alejandro R. Trevino MD^a, Luis Perez MD^a, Carlos Jerjes-Sanchez MD^{a,b*}, David Rodriguez MD^{a,b}, Jathniel Panneflek MD^b, Claudia Ortiz-Ledesma MD^b, Francisco Nevarez, MD^b Vicente Jimenez MD^a, Felipe Valdes MD^a, Eduardo de Obeso MD^a.

^aInstituto de Cardiología y Medicina Vascular, TecSalud. Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey, San Pedro Garza García, Mexico. ^bCentro de Investigación Biomedica, Hospital Zambrano Hellion, TecSalud. Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey, San Pedro Garza García, Mexico.

ORCID ID:

Carlos Jerjes-Sanchez: <https://orcid.org/0000-0003-3222-7405>

David Rodriguez: <https://orcid.org/0000-0002-0811-4235>

Jathniel Panneflek: <https://orcid.org/0000-0003-2479-9462>

Claudia Ortiz-Ledesma: <https://orcid.org/0000-0002-3509-9632>

Francisco Nevarez: <https://orcid.org/0000-0003-0818-8880>

***Corresponding author:** Carlos Jerjes-Sanchez, Instituto de Cardiología y Medicina Vascular, TecSalud y Escuela de Medicina y Ciencias de la Salud. Tecnológico de Monterrey, San Pedro Garza García, Nuevo León, Mexico. Email: jerjes@prodigy.net.mx; carlos.jerjes@udicem.org.mx

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Keywords: Apixaban, pulmonary embolism, intermediate high-risk pulmonary embolism, thrombolysis, NOACs, sPESI.

Short running head: NOACs and sPESI failure in high-risk PE

Declaration of interest: None.

Download English Version:

<https://daneshyari.com/en/article/10217199>

Download Persian Version:

<https://daneshyari.com/article/10217199>

[Daneshyari.com](https://daneshyari.com)